Resectable Hepatocellular Carcinoma
Conditions
Keywords
carcinoma,hepatocellular, liver neoplasms, hepatectomy, mortality, prognostic
Brief summary
Hepatocellular carcinoma is a type of liver cancer and is one of the leading causes of global cancer death. Surgical resection of the afflicted areas of the liver is one of the treatment methods for this condition. In this retrospective research, the investigators explore the outcomes of liver resection for hepatocellular carcinoma patients undergoing liver resection from 2010 to 2021 in Cipto Mangunkusumo General Hospital, Jakarta. The main outcome is mortality and the secondary outcomes are factors predicting mortality after resection.
Detailed description
Study design This is a retrospective cohort study. Treatment of Hepatocellular Carcinoma Patients in RSCM HCC patients are managed by a multidisciplinary team (MDT) consisting of hepatologists, radiologists, pathologists, radiation oncologists, surgeons, and other specialists related to the patient's condition. Confirmed HCC patients are discussed in a weekly MDT team meeting. The meeting assigned patients to treatment options according to the Barcelona Clinic Liver Center (BCLC) staging system, patient preference, and other clinical considerations. Resection is considered for patients at very early (BCLC 0) or early (BCLC A) HCC stages. This includes CP class A patients with a single tumor or less than three small (\<3 cm) tumors. Patients assigned to surgical resection underwent either laparoscopic or open surgery. One to four segments of the liver were removed. Tissue samples were taken for further pathologic examination. Ethical Clearance The ethics committee of The Faculty of Medicine, University of Indonesia, approved this study by giving an ethical clearance with protocol number 19-11-1313. Informed consent was taken from all patients.
Interventions
PROCEDURELiver Resection
Resection of a part of the liver afflicted by hepatocellular carcinoma
Sponsors
Dr Cipto Mangunkusumo General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients undergoing liver resection in Cipto Mangunkusumo hospital due to a confirmed diagnosis of hepatocellular carcinoma from 2010 to 2021
Exclusion criteria
* Patients undergoing liver resection in other hospitals were excluded, even though diagnosis or further care is done in Cipto Mangunkusumo hospital * Patients with other malignancies * Patients undergoing other treatment methods for hepatocellular carcinoma.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | Through study completion, an average of 3 years | Mortality status of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sex | Within one week before surgery | Male or Female |
| Etiology | Within one month before surgery | Divided into hepatitis B, hepatitis C, and non-hepatitis in accordance with the laboratory results. |
| Child-Pugh classification | Within one month before surgery | Divided into Chilld-Pugh A,B, and C using clinical (presence of encephalopathy or ascites) and laboratory (prothrombin time, albumin, and bilirubin levels) data. |
| BCLC Classification | Within one month before surgery | Divided into Stages 0 and A to D using performance status, child-pugh classification, number and size (in cm) of the tumor. |
| AFP Levels | Within one month before surgery | Divided into \<400 and \>=400 |
| Number of tumors | Within one month before surgery | Divided into single and multiple tumors according to imaging findings |
| Age | Within one week before surgery | Age in years |
| Surgery method | During surgery | Laparoscopy or open surgery |
| Segments resected | During surgery | 1-4 segments |
| Cirrhosis | Within one month after surgery | Presence of cirrhosis in histopathological findings |
| Edmondson's grading | Within one month after surgery | Histopathological grading divided into 1 to 4 |
| Tumor differentiation | Within one month after surgery | Histopathological grading divided well, moderate, moderate to poor, and poor |
| Length of stay | An average of two weeks | Measured in days from admission to discharge |
| Largest diameter of tumor | Within one month before surgery | Measured in cm according to imaging |
Countries
Indonesia
Outcome results
None listed